Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Business
  • Real Estate
  • Technology
  • Artificial Intelligence
  • Health
ncarol.com

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing
ncarol.com/10251295

Trending...
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand - 107
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position - 104
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation - 103
WILMINGTON, N.C. ~ Thermo Fisher Scientific Inc., the world leader in serving science, has announced the expansion of its PPD clinical research business with the addition of mycoplasma and biosafety testing capabilities at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. This new service, offered by the analytical testing service of the clinical research business, aims to ensure that biopharmaceutical products are free of contaminants, ultimately delivering safe medicines to patients.

According to Sebastian Pacios, M.D., senior vice president and president of clinical research at Thermo Fisher Scientific, this expansion further strengthens their ability to help customers make the world healthier and solidifies their leadership in this important area. He also notes that there is a growing global need for biosafety testing, especially with the discovery of new cell and gene therapy targets and the expansion of treatments. By adding biosafety testing to their portfolio, Thermo Fisher can provide a comprehensive solution for their GMP lab customers and accelerate the full panel of tests to deliver life-changing therapies as quickly as possible.

More on ncarol.com
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Designed for Healthcare: How TOLI Is Rethinking Functional Flooring
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth

Mycoplasmas are one of the smallest known free-living organisms and can be difficult to detect in mammalian cell cultures. To ensure product quality and patient safety, organizations follow GMP guidelines and strict risk mitigation plans to detect mycoplasmas early on. This not only helps avoid costly delays or remediation but is also a regulatory requirement for lot-release testing. The traditional mycoplasma testing method can take up to a month to generate results. However, with the new quantitative polymerase chain reaction (qPCR) version that incorporates nucleic acid testing, results can now be obtained within five days. This faster turnaround time has led to a 50% utilization rate and is prompting more organizations to switch over to nucleic acid testing.

The rise in chronic diseases such as cancer, neurological disorders, and heart disease has resulted in an increased demand for drugs, cell therapies, diagnostics, and other biological products. To ensure their safety, regulatory requirements mandate testing for the presence of pathogens, including mycoplasma. This has led to a growing demand for mycoplasma testing products. Nucleic acid analysis is the preferred method for this testing due to its accuracy, speed, and flexibility, allowing for quick delivery of medicines to patients.

More on ncarol.com
  • ICG Homes Breaks Ground on the Triangle's 2027 St. Jude Dream Home
  • KayeDinero Takes Viewers Above Asheville in "Autumn in the Blue Ridge" Aerial Visual
  • PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine

The PPD Laboratory services team's GMP lab in Middleton offers fully integrated solutions for pharmaceutical product development. This includes method development and validation, compendial verifications, stability testing, quality control and release testing. The lab also specializes in biologics testing such as cell and gene therapy product development and is a market leader in the analysis of small molecule, inhalation products, medical device functionality testing, as well as extractables and leachables testing.

Apart from the GMP and bioanalytical labs in Middleton, Thermo Fisher's clinical research business also includes bioanalytical, biomarker and vaccine sciences labs in Richmond, Virginia; a GMP lab in Athlone, Ireland; central labs and biomarker operations in Brussels, Belgium; Highland Heights, Kentucky; and Singapore; as well as bioanalytical, biomarker, vaccine sciences and central labs in Suzhou China.

With this expansion of services at their GMP lab in Middleton and their global presence in various areas of clinical research and testing capabilities,Thermo Fisher Scientific continues to solidify its position as a leader in serving science and helping customers deliver safe medicines to patients worldwide.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Nious Media Expands Gaming Coverage With 2026 Game & Geek Expo Special
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Dark Chocolate Nutcracker Marks 15 Years
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • After Nvidia's 14% Drop, Asheville Artist KayeDinero Releases "Nvidia"
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently
  • Gabby Press Earns High Praise From BookLife For Book About the Dangers of Corporate AI
  • Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
  • CB Stuffer Announces Private Sale to Secure Future of Brand Growth
  • The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
  • Apex Wellness Architect Hosts Intimate Tea & Intentions Tea Bar Experience to Close Out the Year
_catLbl0 _catLbl1

Popular on ncarol.com

  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 223
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform - 219
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 196
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 138
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs - 131
  • 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST) - 127
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 125
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers - 120
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA) - 118
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight - 111

Similar on ncarol.com

  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute